| Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440] | Technology appraisal guidance | |
| Slide sheets for repositioning or moving a person: late stage assessment | Health technology evaluation | |
| Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246] | Technology appraisal guidance | TBC |
| Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439] | Technology appraisal guidance | |
| Somapacitan for treating growth hormone deficiency in people 3 to 17 years [ID6178] | Technology appraisal guidance | |
| Sotatercept for treating pulmonary arterial hypertension [ID6163] | Technology appraisal guidance | |
| Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091 | Technology appraisal guidance | TBC |
| Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632 | Technology appraisal guidance | TBC |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287] | Technology appraisal guidance | |
| SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals) | Medical technologies guidance | TBC |